NAT10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Orantinib (SCHEMBL134661)	1.00	1/20
Orantinib (SCHEMBL134662)	1.00	1/20
Orantinib (SCHEMBL900355)	1.00	1/20
Orantinib (SCHEMBL29354645)	1.00	1/20
SCHEMBL12020869	0.84	1/20
SCHEMBL25717271	0.82	1/20
SCHEMBL13497857	0.79	1/20
SCHEMBL26023377	0.79	1/20
SCHEMBL4408682	0.78	1/20
SCHEMBL4408686	0.78	1/20
SCHEMBL29678231	0.78	1/20
SCHEMBL30676938	0.78	1/20
SCHEMBL4405035	0.77	1/20
SCHEMBL4405036	0.77	1/20
SCHEMBL4417269	0.76	1/20
SCHEMBL4417271	0.76	1/20
SCHEMBL12596436	0.74	1/20
SCHEMBL4409721	0.74	1/20
SCHEMBL4409722	0.74	1/20
SCHEMBL4410717	0.74	1/20

Clinical trials — most relevant to NAT10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer	PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension	PHASE2	NOT_YET_RECRUITING
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer	PHASE2	COMPLETED
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy	nan	COMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Genetic Investigation of Cancer Predisposition	nan	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans	nan	ACTIVE_NOT_RECRUITING
Gene Expression and Inflammation in Overweight Subjects	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NAT10 binder may also engage these)

Protein	Name	Similarity
Q8K224	—	1.000	Q8K224 →
P87115	—	0.997	P87115 →
P53914	—	0.997	P53914 →
Q9M2Q4	—	0.996	Q9M2Q4 →
Q9XIK4	—	0.995	Q9XIK4 →
Q9W3C1	—	0.995	Q9W3C1 →
Q55EJ3	—	0.992	Q55EJ3 →
O42131	—	0.990	O42131 →
Q803R5	—	0.990	Q803R5 →
P42348	—	0.989	P42348 →
TOP2B	DNA topoisomerase 2-beta	0.989	landscape →
Q38899	—	0.988	Q38899 →
O01757	—	0.988	O01757 →
Q9UJA3	—	0.988	Q9UJA3 →
O46374	—	0.988	O46374 →
Q29G21	—	0.988	Q29G21 →
Q64511	—	0.987	Q64511 →
Q64399	—	0.987	Q64399 →
Q5F310	—	0.987	Q5F310 →
O42130	—	0.987	O42130 →
Q6NUA1	—	0.987	Q6NUA1 →
Q9VN03	—	0.987	Q9VN03 →
Q24087	—	0.987	Q24087 →
P45437	—	0.987	P45437 →
Q26454	—	0.986	Q26454 →
Q6GNS3	—	0.986	Q6GNS3 →
Q8BU03	—	0.986	Q8BU03 →
Q10QS7	—	0.986	Q10QS7 →
PSMD2	26S proteasome non-ATPase regulatory subunit 2	0.986	landscape →
Q295E6	—	0.986	Q295E6 →